+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06985472

Phase II Study of Orelabrutinib with Zuberitamab for Initial Treatment of Marginal Zone Lymphoma

Led by Li Zhiming · Updated on 2025-05-22

33

Participants Needed

2

Research Sites

108 weeks

Total Duration

AI-Summary

What This Trial Is About

Marginal Zone Lymphoma MZL is a type of B-cell cancer found in areas like the spleen, lymph nodes, and mucosa-associated lymphoid tissues. Researchers are evaluating the combination of two drugs, Orelabrutinib and Zuberitamab, to see how well and how safely they work as the first treatment for MZL. This study is a multi-center, prospective cohort trial focusing on the complete response rate after treatment. Participants receive six cycles of induction therapy with Orelabrutinib and Zuberitamab given together. After this, patients continue with the combination therapy every two cycles for another six cycles, unless the disease worsens or side effects become intolerable. Orelabrutinib is taken orally daily, and Zuberitamab is administered intravenously on specific days of the treatment cycles. During the study, participants undergo imaging tests like CT or MRI scans to measure treatment response. Researchers monitor safety and record outcomes such as the one-year complete response rate and other measures over two years. The study involves regular assessments to track disease status, side effects, and overall health, with participation lasting through the full treatment and follow-up periods.

CONDITIONS

Brief Title

Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL

Research Team

Z

Zhiming Li, professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here